[Brachial plexitis and myelitis and herpes-zoster lumbar plexus disorder in patient treated with infliximab].
Infliximab, a chimeric monoclonal antibody, is a TNF-a inhibitor approved for use in refractory rheumatoid arthritis and Crohn s disease. We present the case of a patient affected by severe rheumatoid arthritis who was successfully treated with infliximab. She suffered diverse neurological complications: brachial plexitis, asymptomatic thoracic myelitis with extensive lesions in MRI study, and herpes zoster lumbar plexitis. We review the neurological adverse effects of infliximab (aseptic meningitis, opportunistic germs infections, disseminated herpes zoster) and focus in their potential adverse effect to induce central and peripheral nervous system demyelination.
Arias
M
M
Servicio de Neurología, Complejo Hospitalario Universitario de Santiago de Compostela, La Coruña. mariasg@meditex.es
Arias-Rivas
S
S
Dapena
D
D
Mera
A
A
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D020968:Brachial Plexus Neuritis / Q000139:chemically induced* / Q000473:pathology; D005260:Female; D006562:Herpes Zoster / Q000139:chemically induced*; D006801:Humans; D000069285:Infliximab; D008160:Lumbosacral Plexus / Q000473:pathology*; D008279:Magnetic Resonance Imaging; D008875:Middle Aged; D009187:Myelitis / Q000139:chemically induced* / Q000473:pathology
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab